Navigation Links
New study refutes existence and clinical potential of very small embryonic-like stem cells

Scientists have reported that very small embryonic-like stem cells (VSELs), which can be isolated from blood or bone marrow rather than embryos, could represent an alternative to mouse and human embryonic stem cells for research and medicine. But their very existence is hotly debated, and a study appearing online on July 24th in the ISSCR's journal Stem Cell Reports, published by Cell Press, provides strong evidence against the existence of VSELs capable of turning into different cell types. The findings call into question current plans to launch a clinical trial aimed at testing whether VSELs can be used for regenerative medicine in humans.

"To know when a stem cell discovery is true, it must meet several criteria," says senior study author Irving Weissman of Stanford University School of Medicine. "First, the work must be published in a peer-reviewed journal; second, other labs in the field should be able to repeat the findings; third, the phenomenon should be so robust that other experimental methods must reveal it; and fourth, in the stem cell field, the regeneration that occurs must be rapid, robust, and lifelong. In our study, we did not find evidence supporting the second, third, and fourth requirements."

In 2006, a group of researchers first reported the presence of VSELs in mice. Subsequent studies have provided evidence that these cells also exist in human blood and bone marrow and could turn into specialized cells such as lung cells, a finding which may be useful for replacing damaged tissue. But other labs have failed to replicate these findings. Nonetheless, a biopharmaceutical company called Neostem, which acquired the exclusive license to VSEL technology, plans to apply for Food and Drug Administration approval to carry out a first-in-man trial to test whether VSELs can regenerate bone.

In light of these conflicting results, Weissman and his team made the most rigorous effort yet to replicate the original VSEL findings. Although they used a variety of protocols, they failed to find VSELs derived from mouse bone marrow that could turn into specialized blood cells. Instead, the "VSELs" appeared to be artifacts such as cell debris and fragments from dying cells. "Our findings clearly refute the basis in mouse studies that VSELs have the potentials claimed, and therefore call into question claims that these cells have potential for clinical application in humans," Weissman says.

Another article that will be published on the same day in the journal Cell Stem Cell reviews the controversy surrounding VSELs and includes wide-ranging commentary from experts in the field.


Contact: Mary Beth O'Leary
Cell Press

Related biology technology :

1. Signal Genetics Announces Publication of BreastPRS™ Validation Study with Weill Cornell Medical College, New York
2. NEBA Health Releases Key Study Results for the first FDA approved brain wave test to help clinicians assess ADHD in children and adolescents
3. Novel study using new technologies outlines importance of California condor social groups
4. 2013 NASA Advanced Technology Phase I Concepts Selected For Study
5. Venaxis APPY1 Test Passes Futility Analysis in Pivotal Clinical Study
6. Study puts troubling traits of H7N9 avian flu virus on display
7. DOs and DON’Ts of Study Start-Up: Best Practices to Improve Efficiency and Meet/Exceed Timelines, New Life Science Webinar Hosted by Xtalks
8. Study Scavenger and Announce Alliance Utilizing Smart Phone Capabilities to Bring Clinical Trials to Motivated Subjects
9. New Approaches in Immunogenicity Assessment Using the New SQiDlite™ System: Case Study Analysis, New Life Science Webinar Hosted by Xtalks
10. New Study Reveals that PEEK Polymer Spinal Cage Is Superior to Titanium in Surgical Treatment of Multilevel Cervical Spondylotic Myelopathy
11. Americord Applauds Study on Stem Cell Therapy for Congenital Heart Defects
Post Your Comments:
(Date:6/27/2016)... June 27, 2016   Ginkgo Bioworks , a ... engineering, was today awarded as one of the ... the world,s most innovative companies. Ginkgo Bioworks is ... the real world in the nutrition, health and ... directly with customers including Fortune 500 companies to ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Researchers at ... most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the ... read it now. , Diagnostic biomarkers are signposts in the blood, lung fluid ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)... SANTA MONICA, Calif. , June 23, 2016  The Prostate Cancer ... to pioneer increasingly precise treatments and faster cures for prostate cancer. Members of ... 77 institutions across 15 countries. Read More About the ... ... ...
Breaking Biology Technology:
(Date:6/16/2016)... FRANCISCO , June 16, 2016 ... size is expected to reach USD 1.83 ... by Grand View Research, Inc. Technological proliferation and ... banking applications are expected to drive the market ... ) , The development of advanced ...
(Date:6/3/2016)... , June 3, 2016 ... von Nepal hat ... Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung ... in der Produktion und Implementierung von Identitätsmanagementlösungen. ... Ausschreibung im Januar teilgenommen, aber Decatur wurde ...
(Date:5/24/2016)... care by providing unparalleled technology to leaders of the medical imaging industry.  As such, ... to the range of products distributed by Ampronix. Photo - ... ... ... With ...
Breaking Biology News(10 mins):